Over the past few years, these newly described small molecule BET inhibitors have been tested in vivo and in vitro and shown to have potent antiproliferative effects not only of NUT (nuclear protein in testis)-midline carcinoma, but also hematologic malignancies, including leukemia and multiple myeloma, and other solid tumors, including lung, thyroid, liver, colorectal, prostate, and skin cancers, neuroblastoma, sarcoma, and brain tumors [21-34]. The gene discussed is NUTM1; the disease is sarcoma.